In vitro activity of Bay y 3118, a new quinolone.

In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs (1995) 1.46

In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother (1997) 1.22

Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin. Antimicrob Agents Chemother (1995) 0.92

Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother (1994) 0.88

Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob Agents Chemother (1994) 0.87

New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1. Antimicrob Agents Chemother (2004) 0.86

The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper. Can J Infect Dis (2004) 0.85

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones. Clin Ophthalmol (2013) 0.83

Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones. Drugs (1995) 0.78

Comparative in vitro activity of BAY Y 3118 against selected species. Drugs (1995) 0.75

In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother (1983) 6.29

The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother (1986) 2.59

Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother (1993) 2.29

In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09

In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother (1991) 1.35

The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone. J Antimicrob Chemother (1993) 1.17

The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin. J Antimicrob Chemother (1991) 1.05

Cross-resistance and cross-susceptibility between fluoroquinolone agents. Eur J Clin Microbiol Infect Dis (1991) 1.02

Mechanisms of resistance to the 4-quinolone antibacterial agents. J Antimicrob Chemother (1990) 1.01

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother (1991) 2.93

In vitro activity of U-76,252 (CS-807), a new oral cephalosporin. Antimicrob Agents Chemother (1988) 1.65

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother (1989) 1.47

In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs. Antimicrob Agents Chemother (1987) 1.32

Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother (1993) 0.93

Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother (1993) 0.93

In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters. Antimicrob Agents Chemother (1990) 0.87

In vitro activity of BAY v 3522, a new oral cephalosporin. Antimicrob Agents Chemother (1990) 0.78

Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med (1989) 0.77

In vitro activity of cefixime, a new oral cephalosporin. Chemioterapia (1988) 0.75